The observed inhibition of PARylation mediated by HDACi highlights the strong potential for PARP and HDAC inhibitors to exhibit a synergistic activity in these hematologic cancer cell lines, as reported previously in cell lines derived from various types of human cancer [15–19, 28]. This evidence concerns the gene PARP1 and hematopoietic and lymphoid cell neoplasm.